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Introduction
Access to antiretroviral (ARV) therapy for patients in
developing countries has become an increasing global
public health and political concern in recent years.
Both donor governments and those of high-burden
countries agree that treating AIDS is a major priority.
Efforts are underway in many countries to increase the
numbers receiving ARV treatment, and the level of
international funds committed to assist this effort has
increased signiﬁcantly, albeit insufﬁciently. In 2002, this
led the World Health Organization (WHO) to launch
an ambitious ‘335’ plan to place three million people
on ARV by 2005 [1].
While numbers beneﬁting from ARV therapy in the
developing world have increased over the last few
years, the need for scaling-up is as urgent as ever: over
two-thirds of the six million people in the developing
world who are in urgent need of ARV therapy live in
sub-Saharan Africa, but less than 2% of these have
access to this treatment. It is estimated that around
6500 people are dying of AIDS each day in this region
[2].
Treating AIDS in the developing world means working
in a context of poor health-care infrastructure and
limited ﬁnancial and human resources, most of which
are concentrated in capital cities. Health-care providers
in the developing world are faced with patients who
have different characteristics to those seen in clinics in
Western countries: half of all cases in developing
countries are among women of childbearing age; there
are much higher proportions of children affected;
patients tend to be in a more critical condition as they
are diagnosed late in the course of the disease; and they
are commonly afﬂicted with one or more complex
comorbidities, such as tuberculosis, malaria and mal-
nutrition.
In moving towards providing sustainable access to
treatment for the majority in the developing world,
models of care must be adapted to the realities of these
regions. Current treatment models have been devel-
oped in Europe and North America, are based on the
availability of more than 20 ARV drugs, assume the
routine use of sophisticated laboratory tools by specia-
lists, and address viral strains that predominate in
wealthy countries. Simpliﬁcation and decentralization
of treatment are therefore essential components of a
successful strategy to extend ARV therapy.
The concept of simpliﬁcation covers the whole process
of providing ARV drugs: inclusion criteria, manage-
ment of side effects, choice of a drug regimen (ﬁrst
line, alternative ﬁrst line and salvage therapy), when to
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a crucial strategy in facilitating adherence, which is a
key condition to optimize the chances of long-term
success for the therapy [3]. Clearly, this is not just
important for resource-poor settings: for example US
guidelines state that ‘regimens should be simpliﬁed as
much as possible by reducing the number of pills and
therapy frequency’ [4].
Simpliﬁcation of the ﬁrst-line regimen has been the
cornerstone of the treatment strategy in developing
countries since triple therapy started to become available
in 2001. While treatment cannot rely on one single
combination alone, the availability of an affordable and
easy-to-use ﬁrst-line regimen is the starting point from
which other strategies can be usefully explored.
This editorial draws on the experience within Me ´de-
cins sans Frontie `res (MSF) to date, based on treating
21,000 people in 27 countries worldwide, together
with information gathered through a series of expert
consultations [5]. It is intended to provide a brief
overview of priorities in adaptation and simpliﬁcation
in developing-country settings.
Simplifying AIDS treatment in the
developing world
The use of ARV drugs for HIV commenced in
Western countries with the launch of zidovudine in
1987. Highly active antiretroviral therapy (HAART)
has been in widespread use in these countries since
1996. Treatment protocols were developed in countries
with high standards of care and few limitations in terms
of monitoring, access to drugs and human resources;
such protocols are complex and require high levels of
technical diagnostic support. There has been little effort
applied to standardizing the ﬁrst-line regimen, except
through academic research [6].
Widespread treatment in developing countries became
a realistic goal in early 2001, when companies produ-
cing generic drugs reduced the price of treatment by
announcing they could provide triple therapy at an
annual cost of US$ 300 [7]. At the same time, it was
clear that it would not be possible to replicate the
Western approach if large numbers of patients were to
be reached. New models were needed that took into
account limited human resources [8], limited availabil-
ity of drugs and lack of access to monitoring tools.
Through practical experience and operational research,
MSF and ministry of health partners have been moving
towards a rationalization of available resources and
simpliﬁcation of strategies. This process has focused on
patient entry criteria, choice of therapy, drug supply
management and delivery of care.
Simpliﬁcation of entry criteria: who to treat?
Quite aside from the complex ethical dilemmas asso-
ciated with achieving fairness in situations of limited
resources [9], there are fundamental practical constraints
to setting inclusion criteria in resource-poor settings.
Health insurance schemes and access to free public care
are very limited in many developing countries, and the
cost of accessing care is placed upon the patient. In
these cases, the only way to ensure access is to offer
free HIV care. MSF has chosen to offer free access to
ARV treatment. In this situation, medical criteria rather
than ability to pay guides decisions about rationing
care.
Laboratory tests that are routinely used for the decision
to begin treatment in wealthy countries are inaccessible
to most people in developing countries. Until accessible
and affordable means of measuring CD4 cell count (or
proxies such as total lymphocyte count) and viral load
become widely available, the decision to start treatment
must rely on clinical staging, which means prioritizing
symptomatic (WHO stages III and IV) patients. Such
triage can be done by clinical ofﬁcers and nurses
provided that they are sufﬁciently trained.
The process of decision making is important and should
incorporate perspectives of both provider and receiver
in a manner that is perceived as fair by the different
stakeholders. In MSF’s experiences, putting those with
greatest risk of death ﬁrst is most in keeping the notion
of fairness held by people living with HIV/AIDS.
In most developing-country settings, prioritization is
not a choice but a practical necessity. It can be argued
that giving priority to the sickest will reduce the
chances of success of treatment. In our experience [10],
severely sick patients can beneﬁt from a signiﬁcant
increase in life expectancy (Table 1). Most patients
arriving at MSF clinics are already sick, with low CD4
cell count (40% of patients treated by MSF programmes
in Africa have CD4 cell count , 50 3 106 cells/l), and
present with opportunistic infections. Nevertheless, the
overall probability of survival is at 85%. The majority
of deaths occur in the ﬁrst trimester, which is probably
a consequence of under- or late diagnosis of opportu-
nistic infections.
The selection process should not become a bottleneck
to scaling-up. As the WHO puts it: ‘It will be crucial
to recognise that there may be no right answers, and
from an ethical perspective, there may be some
answers that are troubling, and even violative of basic
conceptions of fairness.’ MSF has made the choice in
some programmes to disband selection committees,
instead referring patients meeting clinical criteria
directly to counsellors for orientation and support for
treatment.
AIDS 2004, Vol 18 No 18 2354Simpliﬁcation of treatment: protocols
The ideal ﬁrst-line treatment would be potent, easy to
use, well tolerated and without major side effects,
contraindications and adverse drug interactions. Such a
therapy would have the advantage of limiting the need
for monitoring for side effects. In addition, it would be
suitable for pregnant women and children. No existing
ﬁrst-line regimen currently fulﬁls all these criteria.
Current guidelines recommend the combination of
two nucleoside reverse transcriptase inhibitors with a
non-nucleoside reverse transcriptase inhibitor or a
protease inhibitor. Considering all ARV drugs cur-
rently available, there are around 1333 possible three-
drug combinations, and over 150 treatment protocols
are in use [11]. However, in resource-poor settings,
standardization of ﬁrst-line therapy is essential because
of the limited availability of medicines and the need to
provide clear recommendations that can be easily
followed.
The most practical choice today is the WHO-
recommended ﬁxed-dose combination of stavudine/
lamivudine/nevirapine [12]. This combination is af-
fordable, easy to use (one pill twice a day) and is also
indicated for pregnant women. A recently published
study from Cameroon demonstrated the excellent
efﬁcacy and safety of this ﬁxed-dose combination [13].
It is well tolerated, requires minimal monitoring and
shows comparable efﬁcacy to the other widely used
non-nucleoside reverse transcriptase-based combina-
tion: lamivudine, stavudine and efavirenz [14].
A major advantage of the nevirapine- over the efavir-
enz-based regimen is that the former is not teratogenic
(a signiﬁcant number of patients in sub-Saharan Africa
are women of child-bearing age) and it is available as
ﬁxed-dose combination pill: this reduces pill burden,
encourages adherence, limits the risk of wrong doses
(thus limiting the risk of resistance development) and
facilitates drug supply management [15]. Quality of
suppliers has been validated by the WHO pre-qualiﬁ-
cation process [16].
Results from MSF HIV/AIDS programmes using this
ﬁxed-dose combination in over 6800 patients (as of
March 2004) are excellent [17]. Of a cohort of adults
followed for over a year, 70% were still on the ﬁxed-
dose combination, 12% had died (62% in the ﬁrst 3
months after initiation of treatment), 7.3% had to stop
this combination and 10% were considered lost to
follow up. Clinical and immunological outcomes were
comparable to Western standards, even in severely ill
patients.
While this ﬁrst-line therapy has broad applicability,
there are limitations. Around 7% of patients in the
MSF ﬁxed-dose combination cohort had to switch
from a nevirapine-based ﬁxed-dose combination regi-
men to one that did not contain nevirapine and was
not available as a ﬁxed-dose combination pill. The
main reasons for the switch were tuberculosis (25%)
and nevirapine-attributed hepatotoxicity and cutaneous
rash (50%). Other limitations include peripheral neuro-
pathy (ﬁve cases reported), lactic acidosis (no case
reported) or lipoatrophy (two cases reported). Possible
adverse drug interactions (nevirapine and rifampicin),
suboptimal efﬁcacy on certain virus groups (group O)
and types (HIV-2), and the risk of rapid development
of drug resistance (especially to nevirapine) were also a
major concern. In our experience, those patients who
had to stop nevirapine did so within 28 days [inter-
quartile range (IQR), 19–114], whereas those who had
to stop stavudine did so after 215 days (IQR, 157–
287).
In all, it is expected that approximately 10% of patients
will need access to an alternative non-nevirapine-based
Table 1. Baseline characteristics and survival probability of 12 058 patients starting antiretro-
viral therapy in Me ´decins sans Frontie `res’ programmes worldwidea.
Demographic characteristics
Female (%) 56
Median age [years (IQR)] 34 (29–40)
Median CD4 cell count [3 106 cells/l (IQR)]a 71 (22–143)




Median follow-up [months (IQR)] 5 (2.1–10)
Percentage followed for . 6 months 42.8
Outcome
Probability of survival at 24 months (IQR) 0.85 (0.84–0.86)
Probability of survival at 24 months taking into account deaths
and lost to follow-up (IQR)
0.73 (0.71–0.75)
IQR, interquartile range.aData up to March 2004.bAvailable for 8487 individuals.
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on the most commonly required drug substitutions:
efavirenz for nevirapine and zidovudine for stavudine.
However, these alternatives are much more expensive,
do not exist as ﬁxed-dose combinations and also have
signiﬁcant side effects (central nervous system toxicity
with efavirenz; anaemia with zidovudine).
New ﬁrst-line regimens need to be developed. The use
of once daily atazanavir has potential in a robust and
less-toxic ﬁrst-line approach, but for pharmakokinetic
reasons, ritonavir must be added which requires refrig-
eration. Unfortunately, several studies do not favour
the use of triple nucleoside analogue regimens [18].
Once daily efavirenz/didanosine/lamivudine or tenofo-
vir/lamivudine/efavirenz could also be advantageous,
but no ﬁxed-dose combination is in the pipeline. There
is a clear role for the pharmaceutical industry to engage
in the development of new drugs and combination for
ﬁrst-line therapy.
Work to improve ﬁrst-line treatments is needed, and is
all the more pressing as second-line treatments are
more expensive, more complex to administer, and
more complex [19]. Given that the expected failure
rate after 1 or 2 years is 20–30%, there is an urgent
need to ensure that affordable and highly effective
second-line treatment can be provided to patients
showing clinical, immunological, or virological failure
to ﬁrst-line regimens.
Currently, there are no ﬁxed-dose combinations for
second-line therapy (patients move from one pill
twice a day to up to 15 pills daily), and the price can
be as much as 10–20 times higher than a generic
ﬁrst-line regimen: in Cameroon, for example, ﬁrst-
line therapy costs US$ 277, while second-line therapy
is over US$ 4000 [19]. Quality generic production of
second-line ﬁxed-dose combinations needs to be
supported.
The treatment of children with AIDS poses a particular
challenge. Because of lack of commercial interest (few
paediatric cases in western countries), some manufac-
turers of ARV drugs do not produce paediatric formula-
tions at all; some molecules are marketed without ever
having been tested for use in children (e.g., tenofovir)
and those paediatric formulations that are produced are
generally more expensive. While the ﬁxed-dose version
of stavudine/lamivudine/nevirapine for adults is avail-
able for about US$ 200 per patient per year, the best
price for the same drugs in paediatric formulations is
approximately US$ 1300 (oral solutions and syrups).
There are no paediatric ﬁxed-dose combinations. For
the second-line regimen of zidovudine/didanosine/
nelﬁnavir, the adult yearly price is US$ 1228; the same
regimen in paediatric powder and syrup formulations
costs US$ 2846 per person per year [20,21].
Some paediatric formulations are sold as syrups, which
are difﬁcult to use, or in powder, which require clean
water (a constraint in resource-poor settings) and are
difﬁcult to distribute and store. The main recourse for
doctors in the ﬁeld is to break adult tablets. However,
few drugs are manufactured as scored, breakable tablets,
nor have they been speciﬁcally studied for use in
children. The only companies taking an interest in
paediatric formulations are those generic companies
based in the developing world: breakable tablets are
produced by companies in India and Thailand, and the
Thai Generic Pharmaceutical Organization is currently
developing a ﬁxed-dose paediatric combination (lami-
vudine/stavudine/nevirapine).
Simpliﬁcation of laboratory testing: minimum
requirements
Lack of capacity for laboratory monitoring should not
be a barrier to starting treatment for patients in clear
medical need, but monitoring will be crucial for
diagnosing treatment failure before the manifestation of
clinical signs. Unfortunately, tools for diagnosis and
monitoring are subjected to the same market dynamics
as medicines: developed primarily for sale in rich
countries and patent protected.
The price, complexity and running requirements of
biological tests used to measure CD4 cell count or viral
load, or to monitor drug side effects, pose signiﬁcant
technical and ﬁnancial obstacles to project implementa-
tion at the community level. The ﬁrst priority for
improving clinical care is access to a practical and
affordable means of measuring CD4 cell count, in
particular to facilitate treatment decisions for asympto-
matic patients and pregnant women. Current means of
measuring CD4 cell count all have their limitations.
Relying on ‘open’ ﬂow cytometry systems and pro-
moting use of generic reagents could reduce the price
of these tests by at least 50%, although use of the ﬂow
cytometer machine itself remains expensive and will be
largely limited to referral centres. Alternative machines
are being deployed on the ﬁeld but some of them await
independent evaluation. A recent evaluation of the
Cyﬂow (PARTEC, Mu ¨nster, Germany) by MSF in
Malawi is encouraging [22]. Costs per test are 3–10
times cheaper than the next alternative (Facscount;
Becton Dickinson, San Jose, California, USA).
However, even if generic reagents are used and funds
are found to buy machines, running requirements such
as steady electrical supply, temperature control and the
need for periodic servicing means that current technol-
ogy will be of limited use away from large cities. There
are two ways to overcome this: development of a
system of transporting samples to reference centres (this
is currently possible) or development of rapid tests that
do not require sophisticated machinery.
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be met. Waiting for clinical failure before changing
drugs will mean higher failure rates. Clinical failure is
often only apparent many months after the ﬁrst
quantiﬁable increase in viral load. Relying on CD4 cell
count criteria has a considerable impact on survival
rate, reducing the effectiveness of salvage therapy by up
to 50%. This average failure rate varies according to the
nature of the ﬁrst- and second-line regimens, and is
even greater if clinical criteria alone are used.
There is a need for a semiquantitative, simple and
inexpensive rapid test to detect early virological failure
and optimize the response to second-line therapy. Until
rapid tests are available and affordable for use in rural
settings, the most practical solution will be to transport
blood samples on ﬁlter paper for polymerase chain
reaction. This method is stable within a wide range of
temperatures and humidities.
Innovative and accessible tools are also needed to
monitor toxicity and support diagnosis of opportunistic
infections. Diagnosing tuberculosis, for example, is
difﬁcult: depending on the number of specimens
examined, Ziehl–Nielsen detects 30–60% of the
culture-positive tuberculosis suspects [23]. Moreover, as
the degree of immunosuppression increases, the fre-
quency of extrapulmonary tuberculosis and myco-
bacteriaemia increases, leading to difﬁcult diagnostic
challenges in places where culture and biopsy are not
readily available [24]. There is also no easy means of
diagnosing tuberculosis in HIV-positive children
[25,26]. (Clinicians must rely on a combination of
clinical score and raﬁography to diagnose pulmonary
tuberculosis.)
Simpliﬁcation of the drug delivery pipeline
One of the main challenges in treating a chronic disease
like HIV/AIDS is to maintain continuity in the drug
supply. Interruptions in drug supply have been put
forward as a major cause of non-adherence [27]. The
use of a ﬁxed-dose combination pill does help to ease
pressure on the supply chain, but few such combina-
tions are available and their further development and
use is being threatened by increasing patent protection
and political pressure against generic manufacture [28].
A constant stock of alternative ﬁrst-line drugs is needed
to enable substitution in case of drug toxicity or
adverse reactions: efavirenz 200 mg/600 mg, nevirapine
200 mg and the dual-combinations zidovudine/lamivu-
dine and stavudine/lamivudine (also needed for the ﬁrst
15 days during nevirapine dose escalation). This means
that a minimum of ﬁve different drug presentations is
needed even for standard adult ﬁrst-line therapy. This
illustrates why simpliﬁcation and standardization of
protocols is necessary to improve drug supply manage-
ment.
The need to refrigerate medicines can be a major
limitation in the tropical world and is an important
reason why the use of ritonavir-boosted protease
inhibitors is limited in MSF programmes. This again
highlights the need for the development of new
medicines that take the developing world context into
account.
Simpliﬁcation of care through integration and
decentralization
Integration of treatment delivery within HIV clinic
services and programmes for prevention of mother-to-
child transmission and tuberculosis, and even within
hospital wards, is key for improving access to ARV
treatment. Health workers need to be made aware of
opportunities for identifying eligible people for ARV
treatment. Such treatment could be integrated within
programmes for prevention of mother-to-child trans-
mission, especially in settings where CD4 cell count
testing is already available for identifying asymptomatic
mothers with signiﬁcant levels of immune depression
(CD4 cell count , 350 3 106 cells/l).
Special attention is needed to the integration of ARV
treatment within tuberculosis treatment programmes.
In Malawi, MSF has noted that tuberculosis pro-
grammes are mostly decentralized while ARV treat-
ment initiation and follow-up is often still very
centralized, resulting in relatively low uptakes for ARV
treatment among HIV-positive patients with tuberculo-
sis (WHO stage III or IV). Most patients with
tuberculosis who are also HIV positive are too weak
and cannot afford to return for additional consultations
for ARV treatment initiation and follow-up while
taking tuberculosis treatment. Therefore, there is a
need for new models where ARV treatment and
follow-up is integrated into tuberculosis programmes
and gradually decentralized.
For scaling-up to be successful, treatment programmes
must be decentralized from urban centres to the com-
munity primary health-care setting. Patients cannot be
expected to travel tens of kilometres every month to
receive life-long treatment, and ARV drugs have to be
delivered as close as possible to where people live in
order to ensure good adherence. Even in resource-poor
and understaffed settings, this could be implemented at
least for the follow-up of stable patients who have
initiated ARV treatment in clinics.
A critical barrier to scaling-up is lack of human
resources. Most resources are focused in the cities, and
a much greater responsibility needs to be given to
nurses, medical assistants and clinical ofﬁcers in con-
sultations, particularly in rural areas. MSF’s experience
in decentralizing care and ARV treatment through a
mobile team in the district of Chiradzulu in the south
of Malawi has been very positive. Local nurses and
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involved in diagnosis and treatment of opportunistic
infections, follow-up of HIV-positive patients stable
with HAART and in counselling and adherence
support. In this way, it was possible to triple capacity in
under a year, from 1000 patients in May 2003 to 3122
patients in March 2004 (of which 2194 were taking
ARV therapy) [8,29].
Simpliﬁcation of patient follow-up for ARV treatment
should be sought in order to increase clinic capacity for
offering access to treatment and to facilitate decentrali-
zation of treatment follow-up, while maintaining an
acceptable quality of care. MSF’s experience in South
Africa [30], Thailand [31] and elsewhere has shown
that careful preparation of patients, by providing educa-
tion on treatment and adherence support, is essential to
good compliance and successful treatment. Patients and
their peers play a central role the provision of treat-
ment. The head of the WHO 335 initiative at the XV
International Conference on AIDS in Bangkok [32]
emphasized the central role for community-based care
delivered by health workers providing ﬁxed-dose com-
binations, with doctors dealing mainly with complica-
tions.
What needs to be done
Progress has been made in recent years towards
treating HIV infection in the developing world. At
the time of the XIII International Conference on AIDS
in Durban, 2000, the lowest yearly cost of treatment
was still more than $US 1500 (in Brazil); prices in
developing countries were generally several times
higher than this, and it was impossible to imagine
widespread access [33]. Today, thanks to generic
competition, that price has dropped to under US$ 200
[34] and an increasing number of developing countries
have started to provide treatment. However, much
more needs to be done to ensure treatment reaches
those in greatest need.
Cost of treatment: a low-cost ﬁrst-line ﬁxed-dose
combination
Through a combination of bulk purchasing and generic
competition, an annual treatment cost of $US 50 is a
realistic aim. Affordability is crucial to good adherence
[35] and the goal should be to ensure that treatment is
provided to patients at as little cost as possible, ideally
free. New combinations for ﬁrst-line therapy are
needed. However, continued political pressure to block
the use of patented medicines threatens to stiﬂe
progress in making simple and affordable treatments
more widely available. The simplicity of ﬁxed-dose
triple combinations makes them attractive for both
developed and developing world settings, but patent
holders are unwilling to cooperate in producing these
combinations, and they are only available through
generic producers to developing countries. Their use
has been discouraged by the US government, which
recently raised false concerns about their quality and
safety [28] despite the fact that several ﬁxed-dose
combinations have been prequaliﬁed by the WHO and
their safety and efﬁcacy is proven through extensive
use in the ﬁeld [17].
Affordable second lines: an absolute necessity
The cost of second-line regimens remains prohibitive
[19]. Differential pricing and generic competition must
be encouraged to bring down the price of these
medicines. Otherwise, many of the patients who are
currently beneﬁting from treatment will be left without
an alternative in case of failure to ﬁrst-line treatments.
Optimal second-line therapy will require good viral
monitoring, as second-line regimens will be less effec-
tive among patients whose failure has to wait to be
determined clinically.
With the full implementation of the WTO TRIPS
Agreements in 2005, access to new drugs and diagnos-
tics is a pressing concern. All new drugs will be subject
to at least 20 years of patent protection in most
countries, which can drive prices up and block cofor-
mulation. Patents must not be a barrier to accessing the
simplest and most affordable treatment, and public
health safeguards in patent law must be used to the full
to ensure that affordable new treatments are available
to all who need them [36].
Diagnostics: a new battle
Recent negotiations have led to price drops for
diagnostic reagents. In April 2004, the Global Fund to
Fight AIDS, Tuberculosis and Malaria, the World
Bank, UNICEF and the Clinton Foundation an-
nounced agreements that secured lower-priced diag-
nostic reagents. Such negotiations must continue.
However, much lower prices would be possible using
simpliﬁed protocols and generic reagents. In general,
the need for feasible and affordable diagnostics is largely
overlooked. Diagnostics should move up both the
donor agenda to help develop and purchase diagnostics
and WHO’s agenda so that clear recommendations are
made and manufacturers prequaliﬁed.
Who will develop new tools for neglected
patients?
Experience across the developing world over the last
few years has demonstrated the feasibility and efﬁcacy
of providing ARV drugs in resource-limited settings. A
recent WHO consultation sought to develop emer-
gency technical and operational recommendations to
guide the scaling-up of ARV therapy in resource-
limited countries [12]. While efforts like these must
continue to help to adapt and simplify treatment, the
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with the development of appropriate and affordable
tools. Training needs are enormous and should be
addressed in all plans.
However, work is needed to adapt and to simplify the
process of delivering treatment to those in greatest
need. More tools are needed to respond to the needs of
neglected patients such as children, patients coinfected
with tuberculosis, and pregnant women.
There is a need for new medicines and diagnostics
tailored to the developing world. Successful innovation
will likely require new approaches to treatment, in-
cluding therapeutic vaccines. Who will develop these
tools? The Western-based pharmaceutical industry has
been effective in rapidly bringing a range of therapeu-
tics for HIV infection onto the market [37], but huge
gaps remain in meeting the needs of people in develop-
ing countries because of poor prospects for proﬁt [38].
This failure of the market has led some to call for AIDS
to be considered as a neglected disease [39].
This is a political challenge that cannot be sidestepped.
The public sector must be willing to take responsibility
for ensuring the development of new medicines and
diagnostics for neglected diseases and neglected pa-
tients. International organizations and funding initia-
tives such as the Global Fund and WHO should
integrate a research component into their strategy.
Today, however, donor funds are insufﬁcient to sustain
even current programmes, let alone provide funds for
research and development. All multilateral initiatives,
including the Global Fund [40] and the WHO 335
[41], are critically underfunded. The international com-
munity has ﬁnally woken up to the urgency of AIDS,
but resources are still inadequate to meet the needs.
This is a critical moment in deciding whether that
awakening includes a practical determination to stem
the devastation of one of the worst epidemics the
world has ever faced.
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